'BioConversations'
Biocon Biologics’ (BBL) revenues for Q1 FY24 saw an over 100% year-on-year growth, driven by the consolidation of the biosimilars business acquired from Viatris, as well as higher sales of commercialized products that is reflected in their market share gains in U.S. & Europe. The robust performance this quarter has given Biocon Biologics the impetus … Continue reading Consolidation of acquired business fuels Biocon Biologics’ growth trajectory
Biocon Biologics Limited (BBL) got off to a promising start to FY24 with an over two-fold increase in first-quarter revenues, truly reflecting the “Power of One” derived from the Company's transformative acquisition of the global biosimilars of its long-term partner Viatris. Driven by market share gains for its commercialized biosimilars in key markets and the … Continue reading Delivering on ‘Power of One’; Biocon Biologics starts FY24 on a Strong Footing with 2-fold Revenue Jump in Q1
Biocon Biologics Ltd (BBL) has ended financial year 2023 (FY23) on a high. The year marks an inflection point in its value creation journey as the acquisition of partner Viatris’ biosimilars business has catapulted the company into the global big league. BBL more than doubled its revenue on a YoY basis to Rs 2,102 crore … Continue reading Biocon Biologics Ends FY23 on a $1 billion Annual Revenue Trajectory
The World Health Organization recently declared that Covid-19 is no longer a global health emergency. While the pandemic threat has waned, there continues to be huge unmet need for affordable essential medicines to treat chronic diseases that kill 41 million people each year. Over the last two decades, Biocon has been at the forefront of … Continue reading Biocon Reports a Robust Business Performance in FY23
Only company from the global biotech industry to be recognized as ‘industry mover’ Biocon (including Biocon Biologics) is proud to be recognized as the “Industry Mover” in the S&P Global Sustainability Yearbook 2023. Biocon is the only company to be named as “Industry Mover” this year from the Biotechnology industry. Biocon is also the only Biotechnology company from … Continue reading Biocon Recognized Among World’s Most Sustainable Companies in S&P Global 2023 Sustainability Yearbook
The world is just emerging from the economic impact of the COVID-19 pandemic. The people who suffered the economic fallout of the pandemic as their incomes shrunk, urgently need of access to cheaper drugs. This has been the case not only in the emerging markets, but also in the developed countries. Generics and biosimilars which … Continue reading Biocon Biologics Reports a Healthy Business Performance in July-September Quarter
The global economy is in its steepest slowdown since 1970. The IMF has forecast that global economic growth will slow to 3.2% in 2022 and 2.9% in 2023 from 6.1% in 2021. While high inflation continues to make headlines across the globe, spiralling healthcare costs need to be addressed. Biosimilars, which provide affordable access to … Continue reading Biocon Biologics Approaching Closure of Transaction to Buy Out Viatris’ Biosimilars Business
Tricolor Distributed Among Children of govt schools, to Communities and Biocon Group’s staff amidst the singing of the National Anthem and National Song The Biocon Group participated in the Diamond Jubilee (75 years) celebrations of India’s Freedom over three days. The Har Ghar Tiranga campaign, initiated by the Government of India, had a good response; the Biocon Group of companies came together to distribute 30,000 flags among schoolchildren, their parents, general public and Biocon’s employees.
Biocon's Chairperson Kiran Mazumdar-Shaw in a QnA with FE’s Srinath Srinivasan, talks about the bold moves Biocon Biologics is making since 2021, including the recent acquisition of Viatris’ global biosimilars business, which will provide it a direct entry into the US & Europe with the acquired commercial engine in developed and key emerging markets. This … Continue reading Expect Biocon Biologics to become a fully integrated global biosimilars firm post Viatris buy: Kiran Mazumdar-Shaw
Biocon Biologics on Monday announced a transformational deal to acquire partner Viatris’ global biosimilars business for up to USD 3.335 billion in cash and stock. The acquisition of the business, which is estimated to generate revenues of USD 1 billion next year, will create a unique, fully integrated global biosimilars enterprise. Kiran Mazumdar-Shaw, Executive Chairperson, … Continue reading The Biocon Biologics-Viatris Transaction Catapults us into The Global Big League: Kiran Mazumdar-Shaw
India's premier biopharmaceutical company Biocon is working on a pipeline of 20 biosimilar drugs or similar but not identical copy of biologic medicines, to tap the upcoming huge opportunity. Biocon, which launched the world's first interchangeable insulin Glargine in the US during the third quarter, has eight approved products. It has biosimilars in oncology like … Continue reading Biocon developing 20 biosimilar products for global markets
By Dr. Viraj Suvarna Is there a real issue about access to diabetes care? Sir Francis Peabody, renowned physician, says, that the secret in the caring of the patient is in caring for the patient. In other words, despite a plethora of options, Indian patients with diabetes still do not have access to comprehensive diabetes … Continue reading Access to diabetes care; if not now, when?
If you are concerned about your breast health, you might be wondering if there are ways to lower the risk of breast cancer? While one cannot do much about a few risk factors such as being a female or getting older, it is still possible to reduce the risk by adopting some healthy lifestyle habits. … Continue reading HOW CAN I REDUCE MY RISK OF BREAST CANCER?
Dr Arun Chandavarkar, Managing Director, Biocon Biologics Ltd., says the structure of the strategic alliance with Serum Institute Life Sciences provides Biocon Biologics with an asset light and accelerated entry into the often overlooked infectious diseases segment. Having established capabilities and a track record of success in biologics, Biocon Biologics’ foray into vaccines and antibodies for … Continue reading ‘Our Alliance with Serum Institute Provides an Accelerated Entry into Vaccines’
Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd. and Serum Institute Life Sciences Private Limited (SILS), a subsidiary of Serum Institute of India Pvt. Ltd, have entered into a historic alliance to impact global health. This alliance will complement the strengths and resources of two leading Indian players in addressing inequitable access both in … Continue reading A Unique & Synergistic Alliance to Impact Global Health
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age (15–49 years). Worldwide, nearly 116 million women (3.4%) are afflicted with this syndrome and in India, around 10% of women are grappling with this syndrome, however, there is a dearth of proper published data on the same.1 Emerging evidence … Continue reading Women With PCOS Need Extra Attention During COVID-19
Introduction to World Health Day April 7 is marked as World Health Day each year to draw attention to areas of concern related to global healthcare. In 2021, the World Health Day campaign focuses on building a fairer and healthier world collectively. It is in response to the fact that the ongoing COVID-19 pandemic has … Continue reading World Health Day 2021: Building a Fairer, Healthier World
By Seema Ahuja The experiences we have in our formative years shape our behaviour for a lifetime. The unconscious biases that we pick up are also developed due to our experiences either at home or in society. That is why, we need to be careful on how we bring up our children, what conversations we … Continue reading Choose To Challenge & Never Give Up
A Blog by Biocon 